nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—EGFR—pharynx cancer	0.768	1	CbGaD
Vandetanib—Bosutinib—EIF2AK1—pharynx cancer	0.00605	0.519	CrCbGaD
Vandetanib—LTK—tongue—pharynx cancer	0.00461	0.0358	CbGeAlD
Vandetanib—LTK—mouth—pharynx cancer	0.0031	0.0241	CbGeAlD
Vandetanib—ORM1—saliva—pharynx cancer	0.0025	0.0195	CbGeAlD
Vandetanib—Afatinib—EGFR—pharynx cancer	0.00217	0.186	CrCbGaD
Vandetanib—PTK6—saliva-secreting gland—pharynx cancer	0.00198	0.0154	CbGeAlD
Vandetanib—ERBB3—mouth—pharynx cancer	0.00169	0.0131	CbGeAlD
Vandetanib—Erlotinib—EGFR—pharynx cancer	0.00153	0.131	CrCbGaD
Vandetanib—PTK6—trachea—pharynx cancer	0.00153	0.0119	CbGeAlD
Vandetanib—TYRO3—brainstem—pharynx cancer	0.0015	0.0117	CbGeAlD
Vandetanib—BLK—lymphoid tissue—pharynx cancer	0.0014	0.0109	CbGeAlD
Vandetanib—RET—neck—pharynx cancer	0.00134	0.0104	CbGeAlD
Vandetanib—BMPR1B—epithelium—pharynx cancer	0.00131	0.0102	CbGeAlD
Vandetanib—STK35—brainstem—pharynx cancer	0.00125	0.00973	CbGeAlD
Vandetanib—RIPK2—parotid gland—pharynx cancer	0.00123	0.00956	CbGeAlD
Vandetanib—FMO1—parotid gland—pharynx cancer	0.00122	0.00948	CbGeAlD
Vandetanib—IRAK4—parotid gland—pharynx cancer	0.0012	0.00934	CbGeAlD
Vandetanib—RIPK2—saliva-secreting gland—pharynx cancer	0.00118	0.00916	CbGeAlD
Vandetanib—IRAK4—saliva-secreting gland—pharynx cancer	0.00115	0.00894	CbGeAlD
Vandetanib—ERBB3—saliva-secreting gland—pharynx cancer	0.00113	0.00877	CbGeAlD
Vandetanib—LTK—head—pharynx cancer	0.00112	0.0087	CbGeAlD
Vandetanib—PLK4—lymphoid tissue—pharynx cancer	0.0011	0.00853	CbGeAlD
Vandetanib—EPHA8—head—pharynx cancer	0.00107	0.00834	CbGeAlD
Vandetanib—FMO3—parotid gland—pharynx cancer	0.00105	0.0082	CbGeAlD
Vandetanib—SLK—parotid gland—pharynx cancer	0.00105	0.00814	CbGeAlD
Vandetanib—FLT4—epithelium—pharynx cancer	0.00103	0.00803	CbGeAlD
Vandetanib—TYRO3—lymphoid tissue—pharynx cancer	0.00103	0.00801	CbGeAlD
Vandetanib—RIPK2—epithelium—pharynx cancer	0.00103	0.00799	CbGeAlD
Vandetanib—LYN—lymphoid tissue—pharynx cancer	0.00102	0.00797	CbGeAlD
Vandetanib—SLK—saliva-secreting gland—pharynx cancer	0.001	0.00779	CbGeAlD
Vandetanib—KDR—neck—pharynx cancer	0.000997	0.00776	CbGeAlD
Vandetanib—MAP4K5—parotid gland—pharynx cancer	0.000994	0.00773	CbGeAlD
Vandetanib—ERBB3—epithelium—pharynx cancer	0.000983	0.00765	CbGeAlD
Vandetanib—Gefitinib—EGFR—pharynx cancer	0.000958	0.0823	CrCbGaD
Vandetanib—FYN—brainstem—pharynx cancer	0.000954	0.00742	CbGeAlD
Vandetanib—MAP4K5—saliva-secreting gland—pharynx cancer	0.000952	0.00741	CbGeAlD
Vandetanib—EPHB6—parotid gland—pharynx cancer	0.00095	0.00739	CbGeAlD
Vandetanib—Bosutinib—EGFR—pharynx cancer	0.000943	0.081	CrCbGaD
Vandetanib—EPHA5—spinal cord—pharynx cancer	0.000933	0.00726	CbGeAlD
Vandetanib—TYRO3—spinal cord—pharynx cancer	0.000933	0.00726	CbGeAlD
Vandetanib—YES1—parotid gland—pharynx cancer	0.000918	0.00714	CbGeAlD
Vandetanib—RET—epithelium—pharynx cancer	0.000911	0.00709	CbGeAlD
Vandetanib—EPHB6—saliva-secreting gland—pharynx cancer	0.000909	0.00708	CbGeAlD
Vandetanib—RIPK2—trachea—pharynx cancer	0.000908	0.00706	CbGeAlD
Vandetanib—VEGFA—trachea—pharynx cancer	0.000905	0.00704	CbGeAlD
Vandetanib—FMO1—trachea—pharynx cancer	0.0009	0.00701	CbGeAlD
Vandetanib—EPHA6—head—pharynx cancer	0.000894	0.00696	CbGeAlD
Vandetanib—IRAK4—trachea—pharynx cancer	0.000886	0.0069	CbGeAlD
Vandetanib—YES1—saliva-secreting gland—pharynx cancer	0.000879	0.00684	CbGeAlD
Vandetanib—FLT3—lymphoid tissue—pharynx cancer	0.000875	0.00681	CbGeAlD
Vandetanib—ERBB3—trachea—pharynx cancer	0.000869	0.00676	CbGeAlD
Vandetanib—PDGFRB—neck—pharynx cancer	0.000863	0.00672	CbGeAlD
Vandetanib—TEK—epithelium—pharynx cancer	0.00083	0.00646	CbGeAlD
Vandetanib—TYRO3—head—pharynx cancer	0.000829	0.00645	CbGeAlD
Vandetanib—EPHA5—head—pharynx cancer	0.000829	0.00645	CbGeAlD
Vandetanib—LYN—head—pharynx cancer	0.000825	0.00642	CbGeAlD
Vandetanib—BMPR1B—head—pharynx cancer	0.000813	0.00632	CbGeAlD
Vandetanib—MAP3K19—head—pharynx cancer	0.000813	0.00632	CbGeAlD
Vandetanib—MAP2K5—parotid gland—pharynx cancer	0.000812	0.00632	CbGeAlD
Vandetanib—KDR—parotid gland—pharynx cancer	0.000812	0.00632	CbGeAlD
Vandetanib—LCK—trachea—pharynx cancer	0.000806	0.00627	CbGeAlD
Vandetanib—AXL—trachea—pharynx cancer	0.000803	0.00625	CbGeAlD
Vandetanib—FLT4—lymphoid tissue—pharynx cancer	0.000795	0.00619	CbGeAlD
Vandetanib—BLK—lymph node—pharynx cancer	0.000792	0.00616	CbGeAlD
Vandetanib—LTK—lymph node—pharynx cancer	0.000783	0.00609	CbGeAlD
Vandetanib—KDR—saliva-secreting gland—pharynx cancer	0.000778	0.00605	CbGeAlD
Vandetanib—MAP2K5—saliva-secreting gland—pharynx cancer	0.000778	0.00605	CbGeAlD
Vandetanib—SLK—trachea—pharynx cancer	0.000773	0.00601	CbGeAlD
Vandetanib—IRAK4—lymphoid tissue—pharynx cancer	0.000772	0.00601	CbGeAlD
Vandetanib—MAP2K5—brainstem—pharynx cancer	0.000762	0.00593	CbGeAlD
Vandetanib—ERBB3—lymphoid tissue—pharynx cancer	0.000757	0.00589	CbGeAlD
Vandetanib—FYN—trachea—pharynx cancer	0.000751	0.00585	CbGeAlD
Vandetanib—SRC—epithelium—pharynx cancer	0.000738	0.00574	CbGeAlD
Vandetanib—MAP4K5—trachea—pharynx cancer	0.000734	0.00571	CbGeAlD
Vandetanib—RIPK2—spinal cord—pharynx cancer	0.000717	0.00558	CbGeAlD
Vandetanib—VEGFA—spinal cord—pharynx cancer	0.000715	0.00556	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—pharynx cancer	0.000711	0.00553	CbGeAlD
Vandetanib—PDGFRB—parotid gland—pharynx cancer	0.000703	0.00547	CbGeAlD
Vandetanib—FGR—lymphoid tissue—pharynx cancer	0.000702	0.00546	CbGeAlD
Vandetanib—RET—lymphoid tissue—pharynx cancer	0.000702	0.00546	CbGeAlD
Vandetanib—EPHB6—trachea—pharynx cancer	0.000702	0.00546	CbGeAlD
Vandetanib—IRAK4—spinal cord—pharynx cancer	0.0007	0.00545	CbGeAlD
Vandetanib—AXL—lymphoid tissue—pharynx cancer	0.000699	0.00544	CbGeAlD
Vandetanib—STK35—head—pharynx cancer	0.000691	0.00538	CbGeAlD
Vandetanib—ERBB3—spinal cord—pharynx cancer	0.000686	0.00534	CbGeAlD
Vandetanib—KDR—epithelium—pharynx cancer	0.000678	0.00528	CbGeAlD
Vandetanib—YES1—trachea—pharynx cancer	0.000678	0.00528	CbGeAlD
Vandetanib—PDGFRB—saliva-secreting gland—pharynx cancer	0.000673	0.00524	CbGeAlD
Vandetanib—FYN—lymphoid tissue—pharynx cancer	0.000654	0.00509	CbGeAlD
Vandetanib—MKNK1—spinal cord—pharynx cancer	0.000644	0.00501	CbGeAlD
Vandetanib—FLT4—head—pharynx cancer	0.000641	0.00498	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—pharynx cancer	0.000639	0.00498	CbGeAlD
Vandetanib—TEK—lymphoid tissue—pharynx cancer	0.000639	0.00498	CbGeAlD
Vandetanib—RIPK2—head—pharynx cancer	0.000637	0.00496	CbGeAlD
Vandetanib—RET—spinal cord—pharynx cancer	0.000636	0.00495	CbGeAlD
Vandetanib—AXL—spinal cord—pharynx cancer	0.000634	0.00493	CbGeAlD
Vandetanib—FMO1—head—pharynx cancer	0.000632	0.00492	CbGeAlD
Vandetanib—ABL1—parotid gland—pharynx cancer	0.000626	0.00487	CbGeAlD
Vandetanib—IRAK4—head—pharynx cancer	0.000622	0.00484	CbGeAlD
Vandetanib—PLK4—lymph node—pharynx cancer	0.000618	0.00481	CbGeAlD
Vandetanib—SLK—spinal cord—pharynx cancer	0.00061	0.00475	CbGeAlD
Vandetanib—ERBB3—head—pharynx cancer	0.00061	0.00475	CbGeAlD
Vandetanib—ABL1—saliva-secreting gland—pharynx cancer	0.0006	0.00467	CbGeAlD
Vandetanib—MAP2K5—trachea—pharynx cancer	0.0006	0.00467	CbGeAlD
Vandetanib—KDR—trachea—pharynx cancer	0.0006	0.00467	CbGeAlD
Vandetanib—FYN—spinal cord—pharynx cancer	0.000593	0.00462	CbGeAlD
Vandetanib—YES1—lymphoid tissue—pharynx cancer	0.00059	0.00459	CbGeAlD
Vandetanib—ABL1—brainstem—pharynx cancer	0.000588	0.00457	CbGeAlD
Vandetanib—PDGFRB—epithelium—pharynx cancer	0.000587	0.00457	CbGeAlD
Vandetanib—STK10—lymphoid tissue—pharynx cancer	0.000585	0.00455	CbGeAlD
Vandetanib—TEK—spinal cord—pharynx cancer	0.00058	0.00451	CbGeAlD
Vandetanib—MAP4K5—spinal cord—pharynx cancer	0.00058	0.00451	CbGeAlD
Vandetanib—MKNK1—head—pharynx cancer	0.000573	0.00446	CbGeAlD
Vandetanib—BMPR1B—lymph node—pharynx cancer	0.000569	0.00443	CbGeAlD
Vandetanib—SRC—lymphoid tissue—pharynx cancer	0.000568	0.00442	CbGeAlD
Vandetanib—FGR—head—pharynx cancer	0.000566	0.0044	CbGeAlD
Vandetanib—RET—head—pharynx cancer	0.000566	0.0044	CbGeAlD
Vandetanib—AXL—head—pharynx cancer	0.000563	0.00438	CbGeAlD
Vandetanib—EPHB6—spinal cord—pharynx cancer	0.000554	0.00431	CbGeAlD
Vandetanib—FMO3—head—pharynx cancer	0.000546	0.00425	CbGeAlD
Vandetanib—YES1—spinal cord—pharynx cancer	0.000535	0.00417	CbGeAlD
Vandetanib—FYN—head—pharynx cancer	0.000527	0.0041	CbGeAlD
Vandetanib—KDR—lymphoid tissue—pharynx cancer	0.000523	0.00407	CbGeAlD
Vandetanib—PDGFRB—trachea—pharynx cancer	0.000519	0.00404	CbGeAlD
Vandetanib—TEK—head—pharynx cancer	0.000515	0.00401	CbGeAlD
Vandetanib—MAP4K5—head—pharynx cancer	0.000515	0.00401	CbGeAlD
Vandetanib—SRC—spinal cord—pharynx cancer	0.000515	0.00401	CbGeAlD
Vandetanib—FLT3—lymph node—pharynx cancer	0.000494	0.00384	CbGeAlD
Vandetanib—EPHB6—head—pharynx cancer	0.000492	0.00383	CbGeAlD
Vandetanib—STK35—lymph node—pharynx cancer	0.000484	0.00376	CbGeAlD
Vandetanib—ABCC1—parotid gland—pharynx cancer	0.000477	0.00371	CbGeAlD
Vandetanib—YES1—head—pharynx cancer	0.000476	0.0037	CbGeAlD
Vandetanib—MAP2K5—spinal cord—pharynx cancer	0.000474	0.00369	CbGeAlD
Vandetanib—KDR—spinal cord—pharynx cancer	0.000474	0.00369	CbGeAlD
Vandetanib—ABL2—lymph node—pharynx cancer	0.000471	0.00367	CbGeAlD
Vandetanib—STK10—head—pharynx cancer	0.000471	0.00367	CbGeAlD
Vandetanib—ABL1—trachea—pharynx cancer	0.000463	0.0036	CbGeAlD
Vandetanib—EGFR—lymph node—pharynx cancer	0.00046	0.00358	CbGeAlD
Vandetanib—SRC—head—pharynx cancer	0.000458	0.00356	CbGeAlD
Vandetanib—PDGFRB—lymphoid tissue—pharynx cancer	0.000452	0.00352	CbGeAlD
Vandetanib—FLT4—lymph node—pharynx cancer	0.000449	0.00349	CbGeAlD
Vandetanib—RIPK2—lymph node—pharynx cancer	0.000446	0.00347	CbGeAlD
Vandetanib—VEGFA—lymph node—pharynx cancer	0.000445	0.00346	CbGeAlD
Vandetanib—FMO1—lymph node—pharynx cancer	0.000443	0.00344	CbGeAlD
Vandetanib—IRAK4—lymph node—pharynx cancer	0.000436	0.00339	CbGeAlD
Vandetanib—ERBB3—lymph node—pharynx cancer	0.000427	0.00332	CbGeAlD
Vandetanib—KDR—head—pharynx cancer	0.000421	0.00328	CbGeAlD
Vandetanib—MAP2K5—head—pharynx cancer	0.000421	0.00328	CbGeAlD
Vandetanib—PDGFRB—spinal cord—pharynx cancer	0.00041	0.00319	CbGeAlD
Vandetanib—ABL1—lymphoid tissue—pharynx cancer	0.000403	0.00314	CbGeAlD
Vandetanib—MKNK1—lymph node—pharynx cancer	0.000401	0.00312	CbGeAlD
Vandetanib—RET—lymph node—pharynx cancer	0.000396	0.00308	CbGeAlD
Vandetanib—LCK—lymph node—pharynx cancer	0.000396	0.00308	CbGeAlD
Vandetanib—FGR—lymph node—pharynx cancer	0.000396	0.00308	CbGeAlD
Vandetanib—ABCG2—parotid gland—pharynx cancer	0.000395	0.00307	CbGeAlD
Vandetanib—AXL—lymph node—pharynx cancer	0.000394	0.00307	CbGeAlD
Vandetanib—ORM1—spinal cord—pharynx cancer	0.000385	0.00299	CbGeAlD
Vandetanib—FMO3—lymph node—pharynx cancer	0.000382	0.00298	CbGeAlD
Vandetanib—SLK—lymph node—pharynx cancer	0.00038	0.00295	CbGeAlD
Vandetanib—ABCG2—saliva-secreting gland—pharynx cancer	0.000378	0.00294	CbGeAlD
Vandetanib—FYN—lymph node—pharynx cancer	0.000369	0.00287	CbGeAlD
Vandetanib—ABL1—spinal cord—pharynx cancer	0.000365	0.00284	CbGeAlD
Vandetanib—PDGFRB—head—pharynx cancer	0.000364	0.00284	CbGeAlD
Vandetanib—MAP4K5—lymph node—pharynx cancer	0.000361	0.00281	CbGeAlD
Vandetanib—TEK—lymph node—pharynx cancer	0.000361	0.00281	CbGeAlD
Vandetanib—ABCC1—trachea—pharynx cancer	0.000353	0.00274	CbGeAlD
Vandetanib—EPHB6—lymph node—pharynx cancer	0.000345	0.00268	CbGeAlD
Vandetanib—YES1—lymph node—pharynx cancer	0.000333	0.00259	CbGeAlD
Vandetanib—STK10—lymph node—pharynx cancer	0.00033	0.00257	CbGeAlD
Vandetanib—ABL1—head—pharynx cancer	0.000325	0.00253	CbGeAlD
Vandetanib—SRC—lymph node—pharynx cancer	0.00032	0.00249	CbGeAlD
Vandetanib—KDR—lymph node—pharynx cancer	0.000295	0.00229	CbGeAlD
Vandetanib—MAP2K5—lymph node—pharynx cancer	0.000295	0.00229	CbGeAlD
Vandetanib—PDGFRB—lymph node—pharynx cancer	0.000255	0.00199	CbGeAlD
Vandetanib—ORM1—lymph node—pharynx cancer	0.000239	0.00186	CbGeAlD
Vandetanib—ABCG2—spinal cord—pharynx cancer	0.00023	0.00179	CbGeAlD
Vandetanib—ABL1—lymph node—pharynx cancer	0.000227	0.00177	CbGeAlD
Vandetanib—ALB—lymph node—pharynx cancer	0.00021	0.00163	CbGeAlD
Vandetanib—ABCC1—lymph node—pharynx cancer	0.000173	0.00135	CbGeAlD
Vandetanib—ABCG2—lymph node—pharynx cancer	0.000143	0.00112	CbGeAlD
Vandetanib—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	7.15e-05	0.000774	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by FGFR—EGFR—pharynx cancer	7.15e-05	0.000774	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by ERBB2—EGFR—pharynx cancer	7.11e-05	0.00077	CbGpPWpGaD
Vandetanib—PDGFRB—DAP12 signaling—EGFR—pharynx cancer	7.08e-05	0.000766	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling by NGF—EGFR—pharynx cancer	7.04e-05	0.000762	CbGpPWpGaD
Vandetanib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	6.98e-05	0.000755	CbGpPWpGaD
Vandetanib—ABL1—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	6.97e-05	0.000754	CbGpPWpGaD
Vandetanib—PDGFRB—MAPK Signaling Pathway—EGFR—pharynx cancer	6.94e-05	0.000752	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—CDH1—pharynx cancer	6.93e-05	0.000751	CbGpPWpGaD
Vandetanib—FYN—Downstream signal transduction—EGFR—pharynx cancer	6.92e-05	0.00075	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CD79A—pharynx cancer	6.92e-05	0.000749	CbGpPWpGaD
Vandetanib—FYN—Signaling by FGFR—EGFR—pharynx cancer	6.89e-05	0.000746	CbGpPWpGaD
Vandetanib—ABCC1—Disease—B4GALT5—pharynx cancer	6.89e-05	0.000746	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ADH7—pharynx cancer	6.88e-05	0.000745	CbGpPWpGaD
Vandetanib—FYN—Signaling by ERBB2—EGFR—pharynx cancer	6.86e-05	0.000742	CbGpPWpGaD
Vandetanib—FYN—DAP12 signaling—EGFR—pharynx cancer	6.82e-05	0.000739	CbGpPWpGaD
Vandetanib—EPHA6—Developmental Biology—EGFR—pharynx cancer	6.82e-05	0.000738	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by NGF—EGFR—pharynx cancer	6.78e-05	0.000735	CbGpPWpGaD
Vandetanib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—pharynx cancer	6.73e-05	0.000728	CbGpPWpGaD
Vandetanib—FYN—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	6.72e-05	0.000728	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CNDP2—pharynx cancer	6.7e-05	0.000725	CbGpPWpGaD
Vandetanib—EGFR—Focal Adhesion—CCND1—pharynx cancer	6.68e-05	0.000723	CbGpPWpGaD
Vandetanib—PDGFRB—DAP12 interactions—EGFR—pharynx cancer	6.66e-05	0.000721	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by FGFR in disease—EGFR—pharynx cancer	6.66e-05	0.000721	CbGpPWpGaD
Vandetanib—PDGFRB—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	6.66e-05	0.000721	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	6.65e-05	0.00072	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by EGFR—EGFR—pharynx cancer	6.6e-05	0.000715	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by EGFR in Cancer—EGFR—pharynx cancer	6.54e-05	0.000708	CbGpPWpGaD
Vandetanib—LYN—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	6.52e-05	0.000706	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by PDGF—EGFR—pharynx cancer	6.51e-05	0.000705	CbGpPWpGaD
Vandetanib—EGFR—Disease—B4GALT5—pharynx cancer	6.49e-05	0.000703	CbGpPWpGaD
Vandetanib—EGFR—Spinal Cord Injury—TP53—pharynx cancer	6.44e-05	0.000697	CbGpPWpGaD
Vandetanib—FYN—Signaling by FGFR in disease—EGFR—pharynx cancer	6.42e-05	0.000695	CbGpPWpGaD
Vandetanib—FYN—DAP12 interactions—EGFR—pharynx cancer	6.42e-05	0.000695	CbGpPWpGaD
Vandetanib—FYN—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	6.42e-05	0.000695	CbGpPWpGaD
Vandetanib—LCK—Signaling by SCF-KIT—EGFR—pharynx cancer	6.41e-05	0.000694	CbGpPWpGaD
Vandetanib—FYN—Signaling by EGFR—EGFR—pharynx cancer	6.36e-05	0.000689	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—CDH1—pharynx cancer	6.35e-05	0.000688	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD79A—pharynx cancer	6.35e-05	0.000688	CbGpPWpGaD
Vandetanib—FYN—Signaling by EGFR in Cancer—EGFR—pharynx cancer	6.3e-05	0.000683	CbGpPWpGaD
Vandetanib—PDGFRB—Focal Adhesion—EGFR—pharynx cancer	6.29e-05	0.000681	CbGpPWpGaD
Vandetanib—FYN—Signaling by PDGF—EGFR—pharynx cancer	6.28e-05	0.00068	CbGpPWpGaD
Vandetanib—LCK—Disease—B4GALT5—pharynx cancer	6.25e-05	0.000677	CbGpPWpGaD
Vandetanib—KDR—Axon guidance—EGFR—pharynx cancer	6.21e-05	0.000672	CbGpPWpGaD
Vandetanib—ABL1—Integrated Breast Cancer Pathway—TP53—pharynx cancer	6.19e-05	0.00067	CbGpPWpGaD
Vandetanib—PDGFRB—B Cell Activation—EGFR—pharynx cancer	6.16e-05	0.000667	CbGpPWpGaD
Vandetanib—LCK—Downstream signaling of activated FGFR—EGFR—pharynx cancer	6.13e-05	0.000664	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD79A—pharynx cancer	6.12e-05	0.000663	CbGpPWpGaD
Vandetanib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	6.11e-05	0.000661	CbGpPWpGaD
Vandetanib—TEK—Hemostasis—TP53—pharynx cancer	6.09e-05	0.00066	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD79A—pharynx cancer	6.07e-05	0.000658	CbGpPWpGaD
Vandetanib—FYN—Focal Adhesion—EGFR—pharynx cancer	6.06e-05	0.000657	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ADH7—pharynx cancer	6.06e-05	0.000656	CbGpPWpGaD
Vandetanib—LCK—Signaling by ERBB4—EGFR—pharynx cancer	6.04e-05	0.000654	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ADH1B—pharynx cancer	6.03e-05	0.000653	CbGpPWpGaD
Vandetanib—LYN—B Cell Activation—EGFR—pharynx cancer	6.03e-05	0.000653	CbGpPWpGaD
Vandetanib—SRC—Senescence and Autophagy in Cancer—TP53—pharynx cancer	6.03e-05	0.000653	CbGpPWpGaD
Vandetanib—FYN—B Cell Activation—EGFR—pharynx cancer	5.94e-05	0.000643	CbGpPWpGaD
Vandetanib—ALB—Folate Metabolism—TP53—pharynx cancer	5.9e-05	0.000639	CbGpPWpGaD
Vandetanib—PDGFRB—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	5.9e-05	0.000639	CbGpPWpGaD
Vandetanib—PDGFRB—MAPK Signaling Pathway—TP53—pharynx cancer	5.83e-05	0.000631	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—B4GALT5—pharynx cancer	5.77e-05	0.000624	CbGpPWpGaD
Vandetanib—LCK—Downstream signal transduction—EGFR—pharynx cancer	5.76e-05	0.000624	CbGpPWpGaD
Vandetanib—LCK—Signaling by FGFR—EGFR—pharynx cancer	5.74e-05	0.000621	CbGpPWpGaD
Vandetanib—LCK—Signaling by ERBB2—EGFR—pharynx cancer	5.71e-05	0.000618	CbGpPWpGaD
Vandetanib—SRC—Focal Adhesion—CCND1—pharynx cancer	5.7e-05	0.000617	CbGpPWpGaD
Vandetanib—FYN—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	5.68e-05	0.000616	CbGpPWpGaD
Vandetanib—LCK—DAP12 signaling—EGFR—pharynx cancer	5.68e-05	0.000615	CbGpPWpGaD
Vandetanib—SRC—Signaling by SCF-KIT—EGFR—pharynx cancer	5.67e-05	0.000614	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	5.67e-05	0.000614	CbGpPWpGaD
Vandetanib—EGFR—Direct p53 effectors—TP53—pharynx cancer	5.62e-05	0.000608	CbGpPWpGaD
Vandetanib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	5.6e-05	0.000606	CbGpPWpGaD
Vandetanib—VEGFA—Axon guidance—EGFR—pharynx cancer	5.58e-05	0.000604	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—CDH1—pharynx cancer	5.58e-05	0.000604	CbGpPWpGaD
Vandetanib—SRC—Disease—B4GALT5—pharynx cancer	5.54e-05	0.0006	CbGpPWpGaD
Vandetanib—VEGFA—Cellular responses to stress—TP53—pharynx cancer	5.52e-05	0.000598	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD79A—pharynx cancer	5.42e-05	0.000587	CbGpPWpGaD
Vandetanib—YES1—Axon guidance—EGFR—pharynx cancer	5.39e-05	0.000584	CbGpPWpGaD
Vandetanib—LCK—Signaling by FGFR in disease—EGFR—pharynx cancer	5.34e-05	0.000579	CbGpPWpGaD
Vandetanib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	5.34e-05	0.000579	CbGpPWpGaD
Vandetanib—LCK—DAP12 interactions—EGFR—pharynx cancer	5.34e-05	0.000579	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ADH1B—pharynx cancer	5.31e-05	0.000575	CbGpPWpGaD
Vandetanib—LCK—Signaling by EGFR—EGFR—pharynx cancer	5.3e-05	0.000573	CbGpPWpGaD
Vandetanib—EGFR—Integrated Breast Cancer Pathway—TP53—pharynx cancer	5.29e-05	0.000572	CbGpPWpGaD
Vandetanib—PLK4—Cell Cycle—TP53—pharynx cancer	5.26e-05	0.000569	CbGpPWpGaD
Vandetanib—LCK—Signaling by EGFR in Cancer—EGFR—pharynx cancer	5.25e-05	0.000568	CbGpPWpGaD
Vandetanib—LCK—Signaling by PDGF—EGFR—pharynx cancer	5.23e-05	0.000566	CbGpPWpGaD
Vandetanib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	5.13e-05	0.000555	CbGpPWpGaD
Vandetanib—SRC—Downstream signal transduction—EGFR—pharynx cancer	5.1e-05	0.000553	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR—EGFR—pharynx cancer	5.08e-05	0.00055	CbGpPWpGaD
Vandetanib—SRC—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	5.08e-05	0.00055	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—B4GALT5—pharynx cancer	5.07e-05	0.00055	CbGpPWpGaD
Vandetanib—SRC—Signaling by ERBB2—EGFR—pharynx cancer	5.05e-05	0.000547	CbGpPWpGaD
Vandetanib—SRC—TGF-beta Signaling Pathway—TP53—pharynx cancer	5.02e-05	0.000544	CbGpPWpGaD
Vandetanib—LCK—B Cell Activation—EGFR—pharynx cancer	4.95e-05	0.000536	CbGpPWpGaD
Vandetanib—EGFR—MAPK Signaling Pathway—TP53—pharynx cancer	4.85e-05	0.000526	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—EGFR—pharynx cancer	4.85e-05	0.000526	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—CDH1—pharynx cancer	4.83e-05	0.000523	CbGpPWpGaD
Vandetanib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	4.73e-05	0.000513	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR in disease—EGFR—pharynx cancer	4.73e-05	0.000512	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR—EGFR—pharynx cancer	4.69e-05	0.000508	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR in Cancer—EGFR—pharynx cancer	4.65e-05	0.000503	CbGpPWpGaD
Vandetanib—SRC—Signaling by PDGF—EGFR—pharynx cancer	4.63e-05	0.000501	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD79A—pharynx cancer	4.63e-05	0.000501	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by NGF—EGFR—pharynx cancer	4.54e-05	0.000491	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD79A—pharynx cancer	4.53e-05	0.00049	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—CCND1—pharynx cancer	4.52e-05	0.00049	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD79A—pharynx cancer	4.51e-05	0.000488	CbGpPWpGaD
Vandetanib—SRC—Focal Adhesion—EGFR—pharynx cancer	4.47e-05	0.000484	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD79A—pharynx cancer	4.46e-05	0.000483	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	4.45e-05	0.000482	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—EGFR—pharynx cancer	4.43e-05	0.00048	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—EGFR—pharynx cancer	4.39e-05	0.000475	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	4.38e-05	0.000474	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—EGFR—pharynx cancer	4.37e-05	0.000473	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CDH1—pharynx cancer	4.37e-05	0.000473	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—CDH1—pharynx cancer	4.25e-05	0.00046	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—EGFR—pharynx cancer	4.22e-05	0.000456	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—EGFR—pharynx cancer	4.21e-05	0.000456	CbGpPWpGaD
Vandetanib—BLK—Immune System—CDH1—pharynx cancer	4.21e-05	0.000455	CbGpPWpGaD
Vandetanib—FGR—Immune System—CDH1—pharynx cancer	4.19e-05	0.000454	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	4.19e-05	0.000454	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—CDH1—pharynx cancer	4.16e-05	0.00045	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—CCND1—pharynx cancer	4.14e-05	0.000448	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CNDP2—pharynx cancer	4.13e-05	0.000447	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—CDH1—pharynx cancer	4.09e-05	0.000443	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—EGFR—pharynx cancer	4.05e-05	0.000439	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—EGFR—pharynx cancer	4.02e-05	0.000435	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—EGFR—pharynx cancer	4e-05	0.000433	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—EGFR—pharynx cancer	3.98e-05	0.000431	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—EGFR—pharynx cancer	3.96e-05	0.000428	CbGpPWpGaD
Vandetanib—FGR—Hemostasis—TP53—pharynx cancer	3.92e-05	0.000425	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—EGFR—pharynx cancer	3.87e-05	0.000419	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CDH1—pharynx cancer	3.85e-05	0.000417	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD79A—pharynx cancer	3.85e-05	0.000417	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—EGFR—pharynx cancer	3.85e-05	0.000417	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—CCND1—pharynx cancer	3.78e-05	0.00041	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	3.74e-05	0.000405	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ADH7—pharynx cancer	3.74e-05	0.000405	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—EGFR—pharynx cancer	3.72e-05	0.000402	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD79A—pharynx cancer	3.71e-05	0.000402	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—EGFR—pharynx cancer	3.64e-05	0.000394	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—EGFR—pharynx cancer	3.55e-05	0.000384	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CDH1—pharynx cancer	3.54e-05	0.000383	CbGpPWpGaD
Vandetanib—MKNK1—Disease—EGFR—pharynx cancer	3.51e-05	0.00038	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CDH1—pharynx cancer	3.41e-05	0.000369	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—EGFR—pharynx cancer	3.4e-05	0.000368	CbGpPWpGaD
Vandetanib—YES1—Immune System—CDH1—pharynx cancer	3.38e-05	0.000366	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD79A—pharynx cancer	3.29e-05	0.000356	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—TP53—pharynx cancer	3.28e-05	0.000355	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ADH1B—pharynx cancer	3.28e-05	0.000355	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—EGFR—pharynx cancer	3.26e-05	0.000353	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—EGFR—pharynx cancer	3.25e-05	0.000351	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—EGFR—pharynx cancer	3.22e-05	0.000349	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TP53—pharynx cancer	3.17e-05	0.000343	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—CCND1—pharynx cancer	3.13e-05	0.000339	CbGpPWpGaD
Vandetanib—ALB—Metabolism—B4GALT5—pharynx cancer	3.13e-05	0.000339	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CDH1—pharynx cancer	3.02e-05	0.000327	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TP53—pharynx cancer	2.98e-05	0.000323	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—EGFR—pharynx cancer	2.97e-05	0.000321	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—EGFR—pharynx cancer	2.92e-05	0.000316	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—EGFR—pharynx cancer	2.87e-05	0.000311	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—EGFR—pharynx cancer	2.85e-05	0.000309	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—EGFR—pharynx cancer	2.83e-05	0.000306	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—EGFR—pharynx cancer	2.82e-05	0.000306	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TP53—pharynx cancer	2.72e-05	0.000295	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—EGFR—pharynx cancer	2.59e-05	0.00028	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CDH1—pharynx cancer	2.58e-05	0.000279	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—EGFR—pharynx cancer	2.56e-05	0.000277	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—EGFR—pharynx cancer	2.53e-05	0.000274	CbGpPWpGaD
Vandetanib—LYN—Immune System—CDH1—pharynx cancer	2.52e-05	0.000273	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—EGFR—pharynx cancer	2.52e-05	0.000273	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CDH1—pharynx cancer	2.51e-05	0.000272	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—EGFR—pharynx cancer	2.49e-05	0.00027	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TP53—pharynx cancer	2.49e-05	0.00027	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—EGFR—pharynx cancer	2.48e-05	0.000269	CbGpPWpGaD
Vandetanib—FYN—Immune System—CDH1—pharynx cancer	2.48e-05	0.000269	CbGpPWpGaD
Vandetanib—BLK—Immune System—EGFR—pharynx cancer	2.46e-05	0.000266	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—EGFR—pharynx cancer	2.46e-05	0.000266	CbGpPWpGaD
Vandetanib—FGR—Immune System—EGFR—pharynx cancer	2.45e-05	0.000265	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—EGFR—pharynx cancer	2.43e-05	0.000263	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—EGFR—pharynx cancer	2.39e-05	0.000259	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TP53—pharynx cancer	2.36e-05	0.000256	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TP53—pharynx cancer	2.35e-05	0.000255	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—pharynx cancer	2.33e-05	0.000252	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—EGFR—pharynx cancer	2.25e-05	0.000244	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CNDP2—pharynx cancer	2.23e-05	0.000242	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CDH1—pharynx cancer	2.15e-05	0.000232	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CCND1—pharynx cancer	2.11e-05	0.000228	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—EGFR—pharynx cancer	2.08e-05	0.000225	CbGpPWpGaD
Vandetanib—ERBB3—Disease—EGFR—pharynx cancer	2.08e-05	0.000225	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—EGFR—pharynx cancer	2.08e-05	0.000225	CbGpPWpGaD
Vandetanib—LCK—Immune System—CDH1—pharynx cancer	2.07e-05	0.000224	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—pharynx cancer	2.06e-05	0.000224	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ADH7—pharynx cancer	2.02e-05	0.000218	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—EGFR—pharynx cancer	1.99e-05	0.000216	CbGpPWpGaD
Vandetanib—YES1—Immune System—EGFR—pharynx cancer	1.98e-05	0.000214	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—pharynx cancer	1.94e-05	0.00021	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CCND1—pharynx cancer	1.93e-05	0.000209	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CCND1—pharynx cancer	1.88e-05	0.000203	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CCND1—pharynx cancer	1.86e-05	0.000201	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—EGFR—pharynx cancer	1.84e-05	0.000199	CbGpPWpGaD
Vandetanib—SRC—Immune System—CDH1—pharynx cancer	1.83e-05	0.000198	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ADH1B—pharynx cancer	1.77e-05	0.000192	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—EGFR—pharynx cancer	1.76e-05	0.000191	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—pharynx cancer	1.71e-05	0.000186	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	1.69e-05	0.000183	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCND1—pharynx cancer	1.69e-05	0.000183	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EGFR—pharynx cancer	1.65e-05	0.000179	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCND1—pharynx cancer	1.63e-05	0.000177	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—pharynx cancer	1.51e-05	0.000164	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—pharynx cancer	1.51e-05	0.000163	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—pharynx cancer	1.48e-05	0.00016	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—pharynx cancer	1.47e-05	0.00016	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—pharynx cancer	1.47e-05	0.000159	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—pharynx cancer	1.46e-05	0.000158	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—pharynx cancer	1.45e-05	0.000157	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—pharynx cancer	1.39e-05	0.000151	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—pharynx cancer	1.39e-05	0.00015	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—pharynx cancer	1.34e-05	0.000145	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—pharynx cancer	1.32e-05	0.000143	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—pharynx cancer	1.28e-05	0.000139	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—pharynx cancer	1.27e-05	0.000137	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—pharynx cancer	1.24e-05	0.000134	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—pharynx cancer	1.24e-05	0.000134	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—pharynx cancer	1.23e-05	0.000133	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—pharynx cancer	1.22e-05	0.000132	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—pharynx cancer	1.22e-05	0.000132	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—pharynx cancer	1.21e-05	0.000131	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—pharynx cancer	1.2e-05	0.00013	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—pharynx cancer	1.16e-05	0.000125	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—pharynx cancer	1.12e-05	0.000121	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—pharynx cancer	1.11e-05	0.00012	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—pharynx cancer	1.07e-05	0.000116	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—pharynx cancer	1.07e-05	0.000116	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—pharynx cancer	1.03e-05	0.000112	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—pharynx cancer	9.97e-06	0.000108	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—pharynx cancer	9.88e-06	0.000107	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—pharynx cancer	9.74e-06	0.000105	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—pharynx cancer	9.54e-06	0.000103	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—pharynx cancer	9.39e-06	0.000102	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—pharynx cancer	8.82e-06	9.55e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—pharynx cancer	8.18e-06	8.86e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—pharynx cancer	8.01e-06	8.67e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—pharynx cancer	7.88e-06	8.54e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—pharynx cancer	7.82e-06	8.47e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—pharynx cancer	6.92e-06	7.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—pharynx cancer	6.81e-06	7.38e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—pharynx cancer	6.56e-06	7.11e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—pharynx cancer	5.81e-06	6.29e-05	CbGpPWpGaD
